Bacterial Meningitis in Burkina Faso: Surveillance Using Field-Based Polymerase Chain Reaction Testing
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In addition to frequent epidemics of group A meningococcal disease, endemic bacterial meningitis due mostly to Neisseria meningitidis, pneumococcus, and Haemophilus influenzae type b is a serious problem in sub-Saharan Africa. The improved ability to identify the etiologic agent in cases of bacterial meningitis will facilitate more rapid administration of precise therapy. METHODS: To describe the epidemiology of bacterial meningitis and evaluate the usefulness of field-based polymerase chain reaction (PCR) testing, we implemented population-based meningitis surveillance in Burkina Faso during 2002-2003 by use of PCR, culture, and antigen detection tests. RESULTS: Among persons aged 1 month to 67 years, the incidences of meningococcal meningitis, pneumococcal meningitis, and Haemophilus influenzae type b meningitis were 19 cases (n=179), 17 cases (n=162), and 7.1 cases (n=68) per 100,000 persons per year, respectively. Of the cases of meningococcal meningitis, 72% were due to N. meningitidis serogroup W135. Pneumococcal meningitis caused 61% of deaths and occurred in a seasonal pattern that was similar to that of meningococcal meningitis. Of cases of pneumococcal meningitis and N. meningitidis serogroup W135 meningitis, 71% occurred among persons >2 years of age. Most patients, regardless of the etiology of their illness and the existence of an epidemic, received short-course therapy with oily chloramphenicol. Compared with culture as the gold standard, the sensitivity and specificity of PCR in the field were high; this result was confirmed in Burkina Faso and Paris. CONCLUSIONS: Precise and rapid identification of etiologic agents is critical for improvement in the treatment and prevention of meningitis, and, thus, PCR should be considered for wider use in Africa. Vaccines against Streptococcus pneumoniae, N. meningitidis (including serogroup W135), and H. influenzae type b all will have a major impact on the bacterial meningitis burden. Antibiotic recommendations need to consider the importance of S. pneumoniae, even during the epidemic season.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The reported sensitivity of PCR for pneumococcal meningitis is high and reached 100% in the majority of conducted studies (median of 100%, range 79%–100%) (Table 1; see also Table S1 in the supplemental material) (49–58).”
From Molecular diagnostics in cerebrospinal fluid for the diagnosis of central nervous system infections (2024) · cites this paper as [58]
In the citing paper
“The sensitivity of bexA PCR ranged from 81% to 100% with a median of 93%, with a specificity ranging from 81% to 100% (median 94%) (54, 58, 65–68).”
From Molecular diagnostics in cerebrospinal fluid for the diagnosis of central nervous system infections (2024) · cites this paper as [58]
In the citing paper
“Other studies looking at single organism-specific PCR or multiplex assays for a variety of organisms, such as H. influenzae, S. pneumoniae, and N. meningitidis, have demonstrated increased sensitivity compared to conventional methods (28–30).”
From Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid Specimens (2016) · cites this paper as [30]
Citations
Cites
Bulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
Bulletin of the World Health Organization
Frick, K. D., Lynch, M. C., West, S. K., Muñoz, B., & Mkocha, H. A. (2003) · Bulletin of the World Health Organization · Cited by 2,660
Corless, C. E., Guiver, M., Borrow, R., Edwards-Jones, V., Fox, A. J., & Kaczmarski, E. B. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.4.1553-1558.2001 · Cited by 607
Serotype Antigens of Neisseria meningitidis and a Proposed Scbemefor Designation of Serotypes
Frasch, C. E., Zollinger, W. D., & Poolman, J. T. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.4.504 · Cited by 460
Tunkel, A. R. (2001) · Cited by 308
Serogroup W135 meningococcal disease in Hajj pilgrims
Taha, M.-K., Achtman, M., Alonso, J.-M., Greenwood, B., Ramsay, M., Fox, A., Gray, S., & Kaczmarski, E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03502-9 · Cited by 267 · cited 1×
“meningitidis serogroup W135 meningitis has been recognized since 1982 [4], but outbreaks have been documented only recently [5-8].”
BackgroundSelf-citationTaha, M.-K. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.2.855-857.2000 · Cited by 260 · cited 2×
“PCR has a high sensitivity and specificity [12, 13, 15], and the lower limit of bacterial concentrations necessary for detection are such that false-positive results caused by transient contamination (e.”
BackgroundSelf-citationFailure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis
Friedland, I. R., Klugman, K. P., & Klugman, K. P. (1992) · The Lancet · doi:10.1016/0140-6736(92)90087-j · Cited by 191 · cited 1×
“Although few data exist with regard to efficacy, the use of chloramphenicol therapy for pneumococcal meningitis may lead to treatment failure [39], a situation that likely will worsen with the spread of chloramphenicol-resistant organisms [40, 41].”
BackgroundEpidemiology of bacterial meningitis in Niamey, Niger, 1981-96.
Campagne, G., Schuchat, A., Djibo, S., Ousseini, A., Cissé, L., & Chippaux, J. (1999) · Europe PMC (PubMed Central) · Cited by 182
Rådström, P., Bäckman, A., Qian, N., Kragsbjerg, P., Påhlson, C., & Olcén, P. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.11.2738-2744.1994 · Cited by 179 · cited 1×
“, nasopharyngeal carriage) are unlikely to occur [22-24].”
BackgroundDeghmane, A., Giorgini, D., Larribe, M., Alonso, J., & Taha, M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02838.x · Cited by 145 · cited 1×
“meningitidis [13, 14]; the bexA gene, for H.”
Self-citationPeltola, H. (2001) · Clinical Infectious Diseases · doi:10.1086/317534 · Cited by 144 · cited 1×
“rogroup A [1-3].”
Prospective Study of a Serogroup XNeisseria meningitidisOutbreak in Northern Ghana
Gagneux, S., Hodgson, A., Smith, T. A., Wirth, T., Ehrhard, I., Morelli, G., Genton, B., Binka, F. N., Achtman, M., & Pluschke, G. (2002) · The Journal of Infectious Diseases · doi:10.1086/339010 · Cited by 125 · cited 1×
“disease epidemics [9, 10].”
Bacterial Meningitis in Malawian Adults: Pneumococcal Disease is Common, Severe, and Seasonal
Gordon, S. B., Walsh, A. L., Chaponda, M., Gordon, M. A., Soko, D., Mbwvinji, M., Molyneux, M. E., & Read, R. C. (2000) · Clinical Infectious Diseases · doi:10.1086/313910 · Cited by 124
MORTALITY FROM PNEUMOCOCCAL MENINGITIS
Baird, D., Whittle, H. C., & Greenwood, B. M. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91985-1 · Cited by 117
Bäckman, A., Lantz, P.-G., Rådström, P., & Olcén, P. (1999) · Molecular and Cellular Probes · doi:10.1006/mcpr.1998.0218 · Cited by 111 · cited 1×
“, nasopharyngeal carriage) are unlikely to occur [22-24].”
BackgroundNeisseria meningitidis Serogroup W135 Isolates Associated with the ET-37 Complex
Popović, T., Sacchi, C. T., Reeves, M. W., Whitney, A. M., Mayer, L. W., Noble, C. A., Ajello, G. W., Mostashari, F., Bendana, N., Lingappa, J., et al. (2000) · Emerging infectious diseases · doi:10.3201/eid0604.000423 · Cited by 107 · cited 1×
“meningitidis serogroup W135 meningitis has been recognized since 1982 [4], but outbreaks have been documented only recently [5-8].”
BackgroundDENTAL PITS IN DECIDUOUS TEETH, AN EARLY SIGN IN TUBEROUS SCLEROSIS
Weits-Binnerts, J. J., Hoff, M., & van Grunsven, M. F. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91548-3 · Cited by 106
Taha, M., du Châtelet, I. P., Schlumberger, M., Sanou, I., Djibo, S., de Chabalier, F., & Alonso, J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.1083-1084.2002 · Cited by 103 · cited 2×
“fluenzae [5, 12, 15]; and the lytA gene, for S.”
BackgroundSelf-citationOutbreaks of serogroup X meningococcal meningitis in Niger 1995–2000
Djibo, S., Nicolas, P., Alonso, J. ‐., Djibo, A., Couret, D., Riou, J. ‐., & Chippaux, J. ‐. (2003) · Tropical Medicine & International Health · doi:10.1046/j.1360-2276.2003.01126.x · Cited by 94 · cited 1×
“disease epidemics [9, 10].”
Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso
Decosas, J., & Koama, J. B. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00455-3 · Cited by 94 · cited 1×
“During the present study, serogroup W135 of the ET-37 clonal complex [5, 6] was the most common meningococcal serogroup identified.”
BackgroundCampbell, J. D., Edelman, R., King, J. C., Papa, T., Ryall, R., & Rennels, M. B. (2002) · The Journal of Infectious Diseases · doi:10.1086/345763 · Cited by 86
[An epidemiological study of purulent meningitis cases admitted to hospital in Dakar, 1970-1979].
Cadoz, M., Denis, F., & Mar, I. D. (1981) · Europe PMC (PubMed Central) · Cited by 84
Woods, C. W., Armstrong, G. L., Sackey, S. O., Tetteh, C., Bugri, S., Perkins, B. A., & Rosenstein, N. E. (2000) · The Lancet · doi:10.1016/s0140-6736(99)03366-8 · Cited by 79 · cited 1×
“Meningitis Surveillance in Burkina Faso • CID 2005:40 (1 January) • 23 short-term strategy of using serogroup A vaccine only as a response to an epidemic [25, 26] or in combination with preventive vaccination [27–29].”
BackgroundVázquez, J. A., Arreaza, L., Block, C., Ehrhard, I., Gray, S. J., Heuberger, S., Hoffmann, S., Kriz, P., Nicolas, P., Olcén, P., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3430-3434.2003 · Cited by 62 · cited 1×
“Characteristics of persons with suspected bacterial meningitis in Burkina Faso in 2002–2003 spiramycin); testing involved use of the disk diffusion technique, as well as the measurement of MICs by Etest (AB Biodisk), as described elsewhere [19].”
MethodSelf-citationEvaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa
MILLER, M. A., Wenger, J. D., Rosenstein, N. E., & Perkins, B. A. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199912000-00005 · Cited by 50 · cited 1×
“Meningitis Surveillance in Burkina Faso • CID 2005:40 (1 January) • 23 short-term strategy of using serogroup A vaccine only as a response to an epidemic [25, 26] or in combination with preventive vaccination [27–29].”
BackgroundPolymerase Chain Reaction Assay and Bacterial Meningitis Surveillance in Remote Areas, Niger
Sidikou, F., Djibo, S., Taha, M. K., Alonso, J. M., Djibo, A., Kairo, K. K., Chanteau, S., & Boisier, P. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0911.030462 · Cited by 49
Self-citationEMERGENCE OF MENINGOCOCCAL MENINGITIS CAUSED BY W135 SEROGROUP IN AFRICA
Denis, F., Rey, J., Amadou, A., Saliou, P., Prince‐David, M., Mboup, S., Cadoz, M., Mar, I. D., & Étienne, J. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91533-1 · Cited by 46 · cited 1×
“meningitidis serogroup W135 meningitis has been recognized since 1982 [4], but outbreaks have been documented only recently [5-8].”
BackgroundRobbins, J. B., Schneerson, R., Gotschlich, E. C., Mohammed, I., Nasidi, A., Chippaux, J., Bernardino, L., & Maiga, M. A. (2003) · Europe PMC (PubMed Central) · Cited by 43
Muhe, L. M., & Klugman, K. P. (1999) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.1999.00417.x · Cited by 41 · cited 1×
“Although few data exist with regard to efficacy, the use of chloramphenicol therapy for pneumococcal meningitis may lead to treatment failure [39], a situation that likely will worsen with the spread of chloramphenicol-resistant organisms [40, 41].”
BackgroundOuter membrane protein serosubtyping ofNeisseria meningitidis
POOLMAN, J. T., & Abdillahi, H. (1988) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963104 · Cited by 39 · cited 1×
“, serogroup, serotype, and serosubtype) of all meningococcal isolates was determined as described elsewhere [17, 18].”
MethodRobbins, J. B., Schneerson, R., & Gotschlich, E. C. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200010000-00001 · Cited by 34 · cited 1×
“short-term strategy of using serogroup A vaccine only as a response to an epidemic [25, 26] or in combination with preventive vaccination [27-29].”
BackgroundHassan-King, M., Baldeh, I., Adegbola, R., Omosigho, C., Usen, S. O., Oparaugo, A., & Greenwood, B. M. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.8.2030-2032.1996 · Cited by 34
du Châtelet, I. P., Gessner, B. D., & Silva, A. D. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00066-4 · Cited by 30
Self-citationBaethgen, L. F., Moraes, C., Weidlich, L., Rios, S., Kmetzsch, C. Í., Silva, M. S. N., Rossetti, M. L. R., & Zaha, A. (2003) · Journal of Medical Microbiology · doi:10.1099/jmm.0.05192-0 · Cited by 27 · cited 1×
“, nasopharyngeal carriage) are unlikely to occur [22-24].”
BackgroundLong-acting oily chloramphenicol for meningococcal meningitis
Lewis, R. F., Dorlencourt, F., & Pinel, J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60723-4 · Cited by 23
Nicolas, P., Raphenon, G., Guibourdenche, M., Décousset, L., Stor, R., & Gaye, A. B. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.1.198-200.2000 · Cited by 23
Vaccines for the prevention of meningococcal disease in children
Soriano-Gabarró, M., Stuart, J. M., & Rosenstein, N. E. (2002) · Seminars in Pediatric Infectious Diseases · doi:10.1053/spid.2002.125861 · Cited by 20 · cited 1×
“Long-term routine prevention strategies may need to address how to make available to Africa the polyvalent meningococcal conjugate vaccines currently under development for developed countries [31-33] rather than solely attempt to develop a monovalent serogroup A conjugate vaccine for use in Africa.”
BackgroundChippaux, J., Debois, H., & Saliou, P. (2002) · Infection · doi:10.1007/s15010-002-3012-2 · Cited by 17 · cited 1×
“Long-term routine prevention strategies may need to address how to make available to Africa the polyvalent meningococcal conjugate vaccines currently under development for developed countries [31-33] rather than solely attempt to develop a monovalent serogroup A conjugate vaccine for use in Africa.”
Background[Bacterial meningitis in Yaoundé (Cameroon) in 1999-2000].
Fonkoua, M., Cunin, P., Sorlin, P., Musi, J., & Martin, P. M. V. (2001) · PubMed · Cited by 16
Chippaux, J., Campagne, G., Djibo, S., Cissé, L., Hassane, A., & Kanta, I. (1999) · Annals of Tropical Medicine and Parasitology · doi:10.1080/00034989958249 · Cited by 10
Research works printed but not linked: 5
- Campagne, 1999, Bulletin of the World Health Organization, 77, 499
- 1982, Lancet, 11, 1335
- 2003, Emerging infectious diseases, 9, 486
- 2001, 19, 3420
- 2001, Bulletin de la Soci t de pathologie exotique (1990), 94, 300
Cited by
O'Brien, K. L., Wolfson, L. J., Watt, J. P., Henkle, E., Deloria-Knoll, M., McCall, N., Lee, E., Mulholland, K., Levine, O. S., & Cherian, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61204-6 · Cited by 2,398
Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis
Brouwer, M. C., Tunkel, A. R., & van de Beek, D. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00070-09 · Cited by 930
ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
van de Beek, D., Cabellos, C., Dzupova, O., Esposito, S., Klein, M., Kloek, A. T., Leib, S. L., Mourvillier, B., Ostergaard, C., Pagliano, P., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.007 · Cited by 919
Global epidemiology of meningococcal disease
Harrison, L. H., Trotter, C. L., & Ramsay, M. E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.063 · Cited by 755
Laboratory medicine in Africa: a barrier to effective health care
Petti, C. A., Polage, C. R., Quinn, T. C., Ronald, A. R., & Sande, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/499363 · Cited by 749
“Two landmark studies published recently have contributed significantly to our understanding of the etiology of febrile illness in Kenya and Burkina Faso and demonstrate the need for physicians to consider alternative diagnoses in their clinical practice [3, 7, 8].”
Background
Metadata
- Authors
- Chatelet, I. P. D., Traore, Y., Gessner, B. D., Antignac, A., Naccro, B., Njanpop-Lafourcade, B.-M., Ouedraogo, M. S., Tiendrebeogo, S. R., Varon, E., & Taha, M. K.
- Affiliations
- Institut Pasteur (FR)
- Ministère De La Santé (BF)
- Hôpital Européen Georges-Pompidou (FR)
- Corresponding author
- Gessner, B. D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-01
- Volume
- 40
- Issue
- 1
- Pages
- 17-25
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2165238552
- Cited by
- 158
- References
- 41
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 11 · 2015: 5 · 2014: 9 · 2013: 10 · 2012: 12
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Keywords
- bacterial meningitis, meningitis surveillance, Neisseria meningitidis serogroup W135, pneumococcal meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, meningococcal epidemics, seasonal patterns, mortality, Burkina Faso
- MeSH terms
- Adolescent, Adult, Aged, Burkina Faso, Child, Child, Preschool, Humans, Infant, Meningitis, Haemophilus, Meningitis, Meningococcal, Meningitis, Pneumococcal, Middle Aged, Neisseria meningitidis, Population Surveillance, Quality Control, Sensitivity and Specificity, Incidence, Polymerase Chain Reaction, Meningitis, Bacterial, Haemophilus influenzae type b
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.